AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04141020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
Study NCT04141020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
Study NCT06414681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
Study NCT06414681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
Study NCT05439525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan technique
Description: The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
Study NCT06356844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resolvin supplement
Description: Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
Study NCT05177731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally by mouth
Study NCT05177731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine for Injection
Description: Intravenous infusion
Study NCT05177731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous infusion
Study NCT05177731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Intravenous infusion
Study NCT05177731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Orally by mouth
Study NCT04956978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Support Tool
Description: Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
Study NCT03116490 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthesia type
Description: RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
Study NCT04432532 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions
Study NCT05375435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy
Description: high-dose glucocorticoids + cyclophosphamide + calcineurin inhibitor
Study NCT05375435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual-therapy
Description: high-dose glucocorticoids + cyclophosphamide/calcineurin inhibitor
Study NCT06199661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APEX
Description: Three phases: warm-up, high-intensity interval training (HIIT) phase, cool-down. A 10-minute warm-up included deep breathing meditation and dynamic joint mobility exercises. Then, a 40-minute strength and balance workout in HIIT format with five different high-intensity (HI) exercises interspersed with five different postural stability recovery exercises. The HI intervals focused on enhancing cardiovascular fitness, muscle strength, and motor performance. The recovery intervals incorporated balance and mobility exercises. The HI exercises lasted 30 seconds for the first three weeks and then increased to 45 seconds in the fourth week while the recovery exercises lasted 60 seconds throughout the entire intervention. The HIIT phase was repeated three times in the 40 minute block. Lastly, a 10-minute cooldown consisting of standing and seated exercises similar to the warm-up.
Study NCT05291221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intratracheal saline
Description: At the end of the operation by 15min, 5ml of 0.9% normal saline was sprayed down the intratracheal tube of patients
Study NCT05291221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intratracheal Dexmedetomidine
Description: At the end of the operation by 15min, Dexmedetomidine (0.5µg/kg, diluted in 5mL saline in a medical spray bottle) was sprayed down the intratracheal tube of patients
Study NCT05291221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intratracheal Lidocaine
Description: At the end of the operation by 15min, (5ml) 2% of lidocaine was sprayed down the intratracheal tube of patients.
Study NCT04707690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraurethral laser therapy
Description: The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
Study NCT04707690 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intraurethral SHAM laser therapy
Description: The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.
Study NCT04795817 — intervention group
Intervention type: DEVICE
Intervention: Transoral Robotic Surgery
Description: Subjects will undergo TORS benign base of tongue resection procedures (i.e., partial glossectomy, epiglottoplasty, epiglottectomy, and/or lingual tonsillectomy) for the treatment of OSA. Concomitant non-robotic surgical procedures may also be performed as part of the subject's treatment for OSA, and can include one or more of the following: uvulopalatopharyngoplasty (UPPP), lateral pharyngoplasty, expansion sphincter pharyngoplasty, palatine tonsillectomy, or a modified uvulopalatoplasty. Nasal surgery such as septoplasty or turbinoplasty can be combined if it is needed.
Study NCT05439525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: 1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness
Study NCT05439525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: 1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness
Study NCT06285227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313
Study NCT04446780 — intervention group
Intervention type: PROCEDURE
Intervention: Mediolateral episiotomy
Description: Cutting of the perineum during vaginal delivery in order to avoid obstetric anal sphincter injury
Study NCT06111144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized training intensity distribution (TID) and mental training using mindfulness
Description: Polarized TID model group with mindfulness program (POL+)
Study NCT06111144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pyramidal training intensity distribution (TID) and mental training using mindfulness
Description: Pyramidal TID model group with mindfulness program (PYR+)
Study NCT06111144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polarized training intensity distribution (TID) without mindfulness
Description: Polarized TID model group without mindfulness program (POL-)
Study NCT06111144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pyramidal training intensity distribution (TID) without mindfulness
Description: Pyramidal TID model group without mindfulness program (PYR-).
Study NCT05763394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polarized workout program
Description: Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.
Study NCT05763394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity workout program
Description: High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
Study NCT05115214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpherePVI™ Catheter
Description: Affera SpherePVI™ Multi-Ablation System
Study NCT05685264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponsegromab
Description: Participants will receive one subcutaneous injection
Study NCT05685264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponsegromab
Description: Participants will receive four subcutaneous injections
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 1)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 1)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 1)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)
Study NCT06525558 — intervention group
Intervention type: PROCEDURE
Intervention: Intestinal resection
Description: This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
Study NCT05902221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin or moxifloxacin
Description: Antibiotic treatment back bone during 12 weeks
Study NCT05902221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin or moxifloxacin + rifampicin
Description: Antibiotic treatment back bone during 12 weeks + rifampicin
Study NCT05240378 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Surgery for cancer as per the stage of the disease and protocol
Study NCT05738460 — intervention group
Intervention type: DRUG
Intervention: antibiotics
Description: Reproductive tract GBS colonization group of mothers during pregnancy，Use of antibiotics
Study NCT05598177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
Study NCT05598177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will pump saline without dexmedetomidine at the same speed as group D.
Study NCT05334927 — intervention group
Intervention type: BEHAVIORAL
Intervention: Medicine Overuse Headache/New Daily Persistent Headache
Description: At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
Study NCT05334927 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chronic Migraine
Description: long-term follow-up
Study NCT05334927 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patients with other types of primary headache
Description: No collection Brain imaging、Cognitive function test、Biological sample
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 2)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 2)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05373134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 400mg OD x 1 week, 400mg BD x 1 week then increased to 400mg TDS and continued
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 2)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1 week placebo(Week 3)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week placebo(Week 3)
Description: 1 week of consecutively consuming oral placebo (1 time/day)
Study NCT05195047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 week of probiotics(Week 3)
Description: 1 week of consecutively consuming oral probiotics (1 time/day)
Study NCT05373134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06480682 — intervention group
Intervention type: RADIATION
Intervention: Dual x-ray scan
Description: Annual whole body scan monitoring bone mineral density for whole body, radius, L1-4 and femur and body composition
Study NCT06480682 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood screen
Description: Three times a year blood samples will be taken to measure: full blood count, ferritin, B12, folate, erythrocyte sedimentation rate (ESR), renal function, liver function, thyroid stimulating hormone (TSH), Free thyroxine (T4), luteinizing hormone (LH), oestradiol, testosterone, follicle-stimulating hormone (FSH), coeliac screen, vitamin D (25(OH)D), Leptin and Ghrelin
Study NCT06480682 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Informed consent; Low energy availability questionnaires for males and females; General health including menstrual status (females)
Study NCT06480682 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measurements
Description: Three times a year participant's measurements will be taken: stature, body mass and body composition (bio-impedence)
Study NCT06480682 — intervention group
Intervention type: PROCEDURE
Intervention: Resting Metabolic rate
Description: Resting metabolic rate will be measured by resting gas analysis. Each participant will lie down for a period of 15 minutes, in the final 5 minutes their expired gases are analysed using a breath-by-breath gas analyser (Cortex).
Study NCT06480682 — intervention group
Intervention type: OTHER
Intervention: Energy expenditure
Description: Energy expenditure was estimated using accelerometery (Genieactive) and activity logs in the participants' normal environment, assessed during 3 weekdays of scheduled dance training and 2 weekend days without scheduled dance training. Focus is on daily energy expenditure
Study NCT04930770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRNA-1273
Description: Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
Study NCT04779905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urinary albumbin/creatinine ratio
Description: detection of microalbuminuria in nafld patients
Study NCT05660954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: * All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.~* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose.
Study NCT05315661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-STEM
Description: mesenchymal stem cells preconditioned with ethionamide
Study NCT04707911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: Social media based intervention using Instagram with up to 3 posts per day for 30 days
Study NCT05185596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography
Description: transesophageal Echocardiography during advanced life support
Study NCT06336980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing Inclusionary Practices in Faith Communities
Description: Congregational inclusion committees will participate in monthly training meetings for approximately 1 year. Each month a new inclusion practice will be introduced and then the committee will be asked to implement it in their congregation. The 11 practice areas are:1) assessing inclusion needs of members, 2) providing opportunities for members with serious mental illness (SMI) to take on roles and responsibilities, 3) creating an inclusion committee, 4) ensuring that members with SMI are welcomed to all events, 5) creating sensory friendly spaces, 6) offer participation opportunities in multiple formats, 7) adopt policies and practices to support inclusion, 8) using inclusive language, 9) ensure that external communications indicate the congregation is welcoming to all, 10) providing support to family members of individuals with SMI, and 11) conducing outreach to mental health support systems. Goals may vary per congregation based on their current practices, needs, and preferences.
Study NCT05358587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided PENG block with 20 mL Local Anesthetic solution
Description: In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
Study NCT05358587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided PENG block with 30 mL Local Anesthetic solution
Description: In this group, US guided PENG block will be performed with 20 ml of Bupivacaine solution (0.25 %). Block will be performed 30 minutes before spinal anesthesia.
Study NCT04932005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD2269
Description: Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg. Part C: Twice daily dosing for 7 days at 10mg, 30mg, 80mg.
Study NCT04932005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: A single oral dose. Part C: Twice daily dosing for 7 days.
Study NCT06285942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: To use of Edoxaban via PEG in patients with an indication to anticoagulation therapy according to current guidelines
Study NCT06285942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Edoxaban
Description: Other DOACs through PEG or subcutaneous heparin or LMWH
Study NCT06294912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent
Study NCT06294912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.
Study NCT06294912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study NCT06294912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study NCT06294912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Study NCT06294912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study NCT05972941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health communications
Description: Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
Study NCT05972941 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health communications
Description: Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.